Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen
| dc.contributor.author | Jacobus, S.J. | |
| dc.contributor.author | Rajkumar, S.V. | |
| dc.contributor.author | Weiss, M. | |
| dc.contributor.author | Stewart, A.K. | |
| dc.contributor.author | Stadtmauer, E.A. | |
| dc.contributor.author | Callander, N.S. | |
| dc.contributor.author | Dreosti, Lydia M. | |
| dc.contributor.author | Lacy, M.Q. | |
| dc.contributor.author | Fonseca, R. | |
| dc.date.accessioned | 2016-09-20T07:49:47Z | |
| dc.date.available | 2016-09-20T07:49:47Z | |
| dc.date.issued | 2016 | |
| dc.description.abstract | Long-awaited results from the the Southwest Oncology Group (SWOG) trial comparing bortezomib–lenalidomide-dexamethasone (VRd) versus lenalidomide-dexamethasone (Rd) as induction treatment for previously untreated multiple myeloma (MM) patients were recently presented (S0777).1 Results justified the early adoption of VRd in the frontline setting over 5 years ago by the NCCN based on Level 2A evidence according to their guidelines.2 The randomized study E1A05 also sought to evaluate VRd superiority over a doublet (Vd), but in the consolidation setting. The trial was closed to enrollment prematurely due to slow accrual. Results reported here include 48 enrolled patients. | en_ZA |
| dc.description.department | Medical Oncology | en_ZA |
| dc.description.librarian | am2016 | en_ZA |
| dc.description.sponsorship | This study was coordinated by the ECOG-ACRIN Cancer Research Group (Robert L Comis, MD, and Mitchell D Schnall, MD, PhD, Group Co-Chairs) and supported by the National Cancer Institute of the National Institutes of Health under award numbers: CA180820, CA180794, CA21115, CA23318, CA66636, CA180790, CA13650, CA189956, CA35412, CA15488, CA180799 and CA21076. | en_ZA |
| dc.description.uri | http://www.sherpa.ac.uk/romeo/issn/2044-5385/ | en_ZA |
| dc.identifier.citation | Jacobus, SJ, Rajkumar, SV, Weiss, M, Stewart, AK, Stadtmauer, EA, Callander, NS, Dreosti, LM, Lacy, MQ & Fonseca, R 2016, 'Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen', Blood Cancer Journal, vol. 6, art. no. e448, pp. 1-3. | en_ZA |
| dc.identifier.issn | 2044-5385 | |
| dc.identifier.other | 10.1038/bcj.2016.55 | |
| dc.identifier.uri | http://hdl.handle.net/2263/56760 | |
| dc.language.iso | en | en_ZA |
| dc.publisher | Nature Publishing Group | en_ZA |
| dc.rights | © The Author(s) 2016. This work is licensed under a Creative Commons Attribution 4.0 International License. | en_ZA |
| dc.subject | NCCN | en_ZA |
| dc.subject | Patients | en_ZA |
| dc.subject | Southwest Oncology Group (SWOG) | en_ZA |
| dc.subject | Multiple myeloma (MM) | en_ZA |
| dc.title | Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen | en_ZA |
| dc.type | Article | en_ZA |